Skip to content
News Center
About Us Careers News Center Contact Us Legal Video Hub Doing Business with Illumina Investors Illumina for Startups Home

Press Releases

Date Title
9 Oct. 2024 Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
7 Oct. 2024 Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024
3 Oct. 2024 Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
3 Sep. 2024 European Court of Justice rules in favor of Illumina in jurisdictional appeal
27 Aug. 2024 FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
13 Aug. 2024 Illumina announces strategy to accelerate value creation
6 Aug. 2024 Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024
5 Aug. 2024 Illumina launches new oncology menu for NovaSeq X Series customers
18 Jul. 2024 Illumina to Present Upcoming Strategy Update
11 Jul. 2024 Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
9 Jul. 2024 Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base
24 Jun. 2024 Illumina completes the divestiture of GRAIL
11 Jun. 2024 Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
4 Jun. 2024 Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
3 Jun. 2024 Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
3 Jun. 2024 Illumina appoints Everett Cunningham Chief Commercial Officer
29 May 2024 Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
28 May 2024 Illumina releases 2023 Corporate Social Responsibility Report
20 May 2024 Anna Richo joins Illumina's Board of Directors
15 May 2024 Illumina To Webcast Upcoming Investor Conference
6 May 2024 Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
3 May 2024 Illumina To Webcast Upcoming Investor Conference
2 May 2024 Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
12 Apr. 2024 Illumina's planned divestment of GRAIL approved by the European Commission
9 Apr. 2024 Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
4 Apr. 2024 Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
8 Feb. 2024 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
9 Jan. 2024 Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
5 Jan. 2024 Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
4 Jan. 2024 Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
4 Jan. 2024 The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.